(Q46527056)

22 December 2017

title

The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study (English)

1 reference

22 December 2017

author name string

C K Chan

1

1 reference

22 December 2017

S J Kempin

2

1 reference

22 December 2017

S K Noble

3

1 reference

22 December 2017

G A Palmer

4

1 reference

22 December 2017

publication date

1 February 1994

1 reference

22 December 2017

published in

Ophthalmology

1 reference

22 December 2017

volume

101

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

289-300

1 reference

22 December 2017

Argon laser photocoagulation for ocular histoplasmosis. Results of a randomized clinical trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Macular Photocoagulation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Macular Photocoagulation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Surgical management of subfoveal choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

At least three human type alpha interferons: structure of alpha 2

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

UCLA conference. Interferon: immunobiology and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Successful treatment of an angiogenic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

1 reference

7 January 2021

Inhibition of in vitro angiogenesis by lymphotoxin and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Comparisons of several biological and physicochemical properties of human leukocyte interferons produced my human leukocytes and by E. coli

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Biologic Effects of Interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

The interferons. Mechanisms of action and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Inhibition of Cell Motility by Interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Treatment of haemangioendotheliomas with alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Interferon alpha 2a for treatment of age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Systemic antiangiogenic therapy for choroidal neovascularization. What is the role of interferon alfa?

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Evaluation of patients with advanced cancer using the Karnofsky performance status

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Auto-immune thrombocytopenia related to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

Interferon-associated retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2894%2931349-2

7 January 2021

10.1016/S0161-6420(94)31349-2

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017